{"url_path":"/sec/sgmo/8-k/2026-02-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-04","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-036792-index.html","accession_number":"0001193125-26-036792","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-036792-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":145,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNumber\n  \n\nDescription\n\n1.1\n  \n[Underwriting Agreement, dated February 3, 2026, by and between Sangamo Therapeutics, Inc. and Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC, as representatives of the underwriters named therein.](d101629dex11.htm)\n\n4.1\n  \n[Form of Pre-Funded Warrant to Purchase Common Stock.](d101629dex41.htm)\n\n4.2\n  \n[Form of Purchase Warrant to Purchase Common Stock.](d101629dex42.htm)\n\n5.1\n  \n[Opinion of Cooley LLP.](d101629dex51.htm)\n\n23.1\n  \n[Consent of Cooley LLP (included in Exhibit 5.1).](d101629dex51.htm)\n\n104\n  \nCover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nSANGAMO THERAPEUTICS, INC.\n\nBy:\n \n\n/s/ SCOTT B. WILLOUGHBY\n\nName:\n \nScott B. Willoughby\n\nTitle:\n \nChief Legal Officer and Corporate Secretary\n\nDated: February 4, 2026"}